Amgen’s Neulasta is set to face its first competition in the US after the FDA approved Mylan’s biosimilar version of the blockbuster cancer infection biologic. Neulasta brought in $4.5 billion ...

The FDA has approved Sandoz’s pegfilgrastim biosimilar, a cheaper version of Amgen’s long-lasting and big-selling white blood cell booster Neulasta. Novartis’ generics and biosimilars ...

In recent years, Cinfa Biotech used its resources to advance B12019, a biosimilar copy of Amgen’s chemotherapy-induced neutropenia drug Neulasta, through clinical trials. B12019 and Neulasta are ...

Coherus BioSciences will see its workforce shrink once again as the result of the recently agreed sale of its Neulasta biosimilar to Accord BioPharma. About 50 employees who are associated with ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options ...

The Niopeg is comparable to the reference biologic drug Neulasta. Nora Pharma ... receiving myelosuppressive anti-neoplastic drugs. The biosimilar Niopeg will be available in Canada in a prefilled ...

Pegfilgrastim biosimilars, including Neulasta, are instrumental in preventing chemotherapy-induced neutropenia by stimulating white blood cell production and reducing infection risks. The Neulasta ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...